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Abstract
The immediate molecular mechanisms behind invasive melanoma are poorly understood. Recent studies implicate
microRNAs (miRNAs) as important agents in melanoma and other cancers. To investigate the role of miRNAs in melanoma,
we subjected human melanoma cell lines to miRNA expression profiling, and report a range of variations in several miRNAs.
Specifically, compared with expression levels in melanocytes, levels of miR-211 were consistently reduced in all eight non-
pigmented melanoma cell lines we examined; they were also reduced in 21 out of 30 distinct melanoma samples from
patients, classified as primary in situ, regional metastatic, distant metastatic, and nodal metastatic. The levels of several
predicted target mRNAs of miR-211 were reduced in melanoma cell lines that ectopically expressed miR-211. In vivo target
cleavage assays confirmed one such target mRNA encoded by KCNMA1. Mutating the miR-211 binding site seed sequences
at the KCNMA1 39-UTR abolished target cleavage. KCNMA1 mRNA and protein expression levels varied inversely with miR-
211 levels. Two different melanoma cell lines ectopically expressing miR-211 exhibited significant growth inhibition and
reduced invasiveness compared with the respective parental melanoma cell lines. An shRNA against KCNMA1 mRNA also
demonstrated similar effects on melanoma cells. miR-211 is encoded within the sixth intron of TRPM1, a candidate
suppressor of melanoma metastasis. The transcription factor MITF, important for melanocyte development and function, is
needed for high TRPM1 expression. MITF is also needed for miR-211 expression, suggesting that the tumor-suppressor
activities of MITF and/or TRPM1 may at least partially be due to miR-211’s negative post transcriptional effects on the
KCNMA1 transcript. Given previous reports of high KCNMA1 levels in metastasizing melanoma, prostate cancer and glioma,
our findings that miR-211 is a direct posttranscriptional regulator of KCNMA1 expression as well as the dependence of this
miRNA’s expression on MITF activity, establishes miR-211 as an important regulatory agent in human melanoma.
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Introduction
Melanoma, a cancer of the pigment-producing cells in the skin
epidermis, can be highly metastatic, and malignant melanomas are
relatively resistant to standard chemotherapy [1]. A major cause for
melanoma initiation isextensiveorintermittent exposure to thesun’s
radiation over a period of time, and the extent of melanin
pigmentation is an important risk factor [2]. The exact molecular
mechanisms that lead to melanoma are complex and poorly
understood [3–6], and may involve both mutagenic DNA lesions
and epigeneticmisregulation [7–11].The complexityisadded by the
involvement of several different signal transduction pathways, such
as the Hedgehog pathway, which controls BCL2-mediated apoptosis;
mutations in the Patched gene, the endpoint of the Hedgehog pathway,
have been correlated with skin cancers [3,12–15]. A frequent
causative mechanism for an inherited form of predisposition to
melanoma is thought to be a chromosomal deletion over 9p21. The
9p21 site harbors the tumor suppressor gene INK4a and
accompanies additional inactivating mutations that lead to the
constitutive activation of genes such as BRAF [16,17]. INK4a
encodes one of several cyclin-dependent protein kinase inhibitors,
which islocatedadjacent to analternatereadingframe of the human
p14
ARF.P 1 4
ARF binds to the Mdm2 protein in several cell lines
(though remains untested in melanoma cell lines, to our knowledge)
and thereby abrogates Mdm2’s binding to p53, causing p53 to be
stabilized and nuclear localized. The loss of INK4a therefore may
lead to interference of two separate pathways of cell cycle control:
CDK signaling and suppression of p53 activity by Mdm2-induced
acceleration of p53 degradation. Methylation near the 59 upstream
region of INK4a has been shown in some 10% of melanomas [7],
suggesting that epigenetic down-regulation of this gene may be
important for melanoma development. The activation of BRAF
alone may be insufficient to cause metastatic melanoma, but
additional mutagenic or epigenetic events such as the inactivation
o ft u m o rs u p p r e s s o rg e n e s ,e.g., Pten [18], may be important. There
is evidence that the NOTCH signalling pathway is important for
distinguishing normal melanocytes from melanoma cells [19,20].
Measurement of genome-wide DNA copy number variations,
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can be used to distinguish among different melanoma subtypes with
reasonable accuracy [21]. Particularly noteworthy is the recent
demonstration of abnormally high oncogenic potentials of single
melanoma cells [22], emphasizing the need for better understanding
the molecular mechanisms of melanoma progression.
Attention has recently focused on the role of small non-coding
RNA molecules in cancer development [23–27] and in melanoma
in particular [28–32]. miRNAs influence cancer development by
serving either as tumor suppressors or oncogenes [33–39] by their
negative regulatory effects on mRNA encoded by oncogenes or
tumor suppressor genes, respectively. With the goal of defining the
genes with major contributions to melanoma, several genome-
wide expression level studies have identified a number of protein-
coding [40] and microRNA (miRNA) genes as important players
[32,41–43]. Several of these genes and their expression signatures
exhibit distinct patterns among malignant metastatic melanomas
and their benign forms, but their significance with respect to
melanoma initiation and progression is poorly understood. For
example, miR-221/222 were found to down-regulate p27Kip1/
CDKN1B and the c-KIT receptor, which controls the progression
of neoplasia leading to enhanced proliferation and reduced
differentiation in melanoma cells [42]. Similarly, high miR-137
expression in melanoma cell lines down-regulates microphthalma
associated transcription factor (MITF), a transcription factor
important for melanocyte cell growth, maturation, apoptosis,
and pigmentation [32]. The depletion of miR-182 reduces
invasiveness and induces melanoma cell death by suppressing
the expression of transcription factors FOXO3 and MITF [43],
suggesting that its increased expression may be associated with
certain aspects of melanoma biology. Relatively less is known
about the downstream genes that are regulated by MITF and
FOXO3, which are evidently important for melanoma progres-
sion and metastasis.
In contrast to miRNAs that are over-expressed in melanoma,
and their respective target genes that are thus under-expressed,
relatively little is known about miRNA species that are
systematically depleted in melanomas. Consequently, their respec-
tive target genes, expected to be up-regulated, which might explain
some of the oncogenic potentials of invasive melanomas, are
largely unrecognized. Realizing this gap in knowledge, we
examined the expression levels of human miRNAs in defined
melanoma cell lines and clinical melanoma samples. We report
here the reduced expression of miR-211 in these cell lines and
clinical isolates of human melanomas, and present evidence that a
principal effect of the reduced expression of miR-211 is the
increased expression of its target transcript KCNMA1. The
expression of KCNMA1, encoding a calcium ion-regulated
potassium channel protein, appears to at least partially account
for the high cell proliferation rate and invasiveness of melanoma
cell lines. We also demonstrate that MITF expression is important
for the coordinate expression of miR-211, and TRPM1. TRPM1
gene is a suppressor of melanoma metastasis, which encodes a
transient receptor potential family member calcium channel
protein, and encodes miR-211 gene in its sixth intron. Here, we
propose a model for the role of miR-211 and its regulation in
melanoma cells.
Results
miR-211 is expressed at a low level in non-pigmented
melanoma cell lines
As the first step in identifying down-regulated miRNAs in
human melanoma, we identified significantly differentially ex-
pressed miRNA species in the melanoma cell line WM1552C
(originally established from a stage 3 skin melanoma of a 72-year-
old patient) compared to those in the normal melanocyte cell line
HEM-l by hybridization of total RNA samples to miRNA probe
arrays (see Methods). Figure 1 lists 24 statistically significant
differentially expressed miRNAs, classified into three groups
according to their significance levels (P,0.01, 0.02, and 0.05,
respectively). To address whether the differential miRNA
expression levels observed with WM1552C varied among other
established melanoma cell lines, we performed quantitative reverse
transcriptase mediated polymerase chain reaction (qRT-PCR)
analysis on RNA isolated from WM1552C and seven additional
non-pigmented melanoma cell lines (see Methods) (Figure 2A),
addressing the expression levels of three separate microRNAs:
miR-let7a, miR-let7g, which were over-expressed, and miR-211
was down-regulated. Northern blot analysis further confirmed
these results (Figure 2B). This consistency provided the opportu-
nity to address the significance of the reduced level of miR-211 in
melanoma. In the following sections we focus on miR-211 and its
target genes as a model of the role of miRNAs that are down-
regulated in melanoma, with the aim of determining the role of
their target genes that are thus up-regulated in melanoma. miR-
211 showed the most robust and consistent changes in expression
levels between melanocytes and non-pigmented melanoma cell
lines. Results reported in Figures 1 and 2 implicate several
additional miRNAs in melanoma; specific studies related to these
miRNAs are beyond the scope of this communication, and will be
reported elsewhere.
miR-211 levels in clinical melanoma samples
We assayed miR-211 transcript levels by qRT-PCR in 30
clinical melanoma samples (six primary, six regional, 12 nodal and
six distal metastatic, respectively; described in Table S1). miR-211
expression levels were reduced in 21 of these clinical samples
compared to that observed in melanocytes (Figure 3, Table S2). In
the remaining nine melanomas, six (one primary, one regional,
two distant, and two nodal metastatic melanomas) showed
statistically significant increases in miR-211 expression, whereas
expression was not significantly different in the remaining samples.
These samples were obtained from different patients; therefore,
the observed differences may reflect different processes in
melanoma development and progression, individual genetic
differences, different proportions of non-melanoma (including
non-pigmented) cells in the tumor samples, or a combination of
these factors. Since the exact proportions of cancer cells in the
frozen melanoma biopsy samples are not known, we are unable to
eliminate the ratio of melanoma to non-melanoma cells as a source
of the variation. Consequently, the determination of specificity and
accuracy of melanoma typing by miR-211 expression were not
addressed in this study. However, miR-211 levels were low in the
majority (21/30) of the tested melanoma clinical samples, a
statistically significant trend (P=0.029, for random distribution by
Fisher’s exact test) that is consistent with the uniformly low
expression levels in all eight melanoma-derived cell lines we
studied. Note that miR-211 expression levels were also observed to
be low in normal skin samples, which is expected given that
melanocytes constitute a minor fraction of skin cells. Additional
miRNAs that were over-expressed in melanoma cell lines relative
to those in melanocytes were also over-expressed in the clinical
melanoma samples but not in the normal skin samples (data not
shown), confirming that normal skin samples are not the ideal
background controls. Although there is no perfect ‘‘normal’’
counterpart tissue for melanoma in clinical skin samples, we have
tested miR-211 expression levels in additional melanocyte cell lines
miRNA-211 in Melanoma
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show that miR-211 is elevated in both melanocyte cell lines
compared to normal human skin (Figure S1). miR-211 expression
levels in pooled samples of nevi also agree with previously
published results, supporting the observation that miR-211 is
highly expressed in nevi compared to melanoma [44]. These
observations are consistent with the understanding that nevi are
composed of melanocytes. Together, these results suggest that the
development of most melanomas is specifically associated with the
depletion of miR-211 transcript levels. An alternative formal
interpretation, which is unlikely considering the absence of
supporting literature, is that the low miR-211 level in melanoma
reflects a cellular origin of melanoma which is distinct from that of
melanocytes.
Stable ectopic expression of miR-211 in melanoma cell
lines depletes select target transcripts
Differential expression of miRNAs in melanoma may be
mechanistically related to melanoma development, or it may be
coincidental. If indeed the depleted miRNAs are biologically
relevant, melanoma cells should be enriched for their target
transcripts levels relative to their corresponding levels in
melanocytes. As the first step to identify such mRNA transcripts,
we hybridized cDNAs made from total RNA isolated from the
melanoma cell line WM1552C and the melanocyte line HEM-l to
Affymetrix expression arrays. We then filtered the hybridization
intensity data for differential expression of computationally
predicted target transcripts of miR-211 (Figure 4) (see Methods).
These experiments revealed 26 putative target transcripts whose
expression levels were elevated relative to those in HEM-l.
If the set of 26 genes indeed contains valid targets of miR-211,
their levels should be depleted if miR-211 levels were to increase in
any melanoma cell line. To directly examine this possibility, we
constructed three independent melanoma cell lines that stably
express miR-211. For that purpose, we transfected the pre-miR-
211 sequence (plasmid pcDNA4/miR-211) into WM1552C and
A375 cells, followed by selection for stable expression of miR-211
and confirmation of expression by qRT-PCR analysis (see
Methods). The melanoma cell line clones that ectopically
expressed miR-211 were named: WM1552C/211(400),
WM1552C/211(800) and A375/211 (see Methods for details).
We measured global mRNA levels in WM1552C/211(400) and
A375/211 cells on Affymetrix arrays and compared these levels
with the corresponding levels measured in the same experiment in
untransfected parental cell lines WM1552C and A375, respec-
tively. This analysis revealed a list of 18 putative target transcripts
for miR-211, which were down-regulated by the artificial
expression of miR-211 in both melanoma cell lines (Figure 5).
When cross-referenced with results reported in Figure 4, nine of
these putative target transcripts were found to be up-regulated in
both melanoma cell lines compared to those in melanocytes and
down-regulated in both melanoma cell lines when miR-211 was
stably expressed. These candidate targets of miR-211 are:
ATP2B1, CDH2, GLIS3, KCNMA1, MEIS2, NCAM-1, NF-AT5,
PRPF38B, and TCF12. Of these, the following seven genes were
previously implicated in cancer progression: ATP2B [45], CDH2
[19,46,47], GLIS3 [48], KCNMA1 [49–51], MEIS2 [52,53],
NCAM-1 [[54], and NF-AT5 [55]. Moreover, CDH2, KCNMA1,
NCAM-1, and NF-AT5 were previously shown to affect metastatic
migration and/or tissue invasion [19,46,47,51,54]. In particular
the expression of KCNMA1, which encodes a component of a K
+
exporting channel whose function is modulated by Ca
++, has been
linked to tumor cell proliferation in prostate cancer [49], cell
migration in glioma [56] and antineoplastic drug resistance in
Figure 1. Differentially expressed miRNA transcripts in the melanoma cell line WM1552C. Histograms of log2 of mean expression ratios of
miRNA levels in WM1552C to that in the untransformed melanocyte cell line HEM-l (control) are plotted as histograms. Asterisks indicate the
respective levels of statistical significance, indicated below the diagram.
doi:10.1371/journal.pone.0013779.g001
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also contains one of the strongest predicted target sites of miR-211.
Therefore we focused on this transcript for investigation.
KCNMA1 protein and transcript levels correlate inversely
with that of miR-211
If miR-211 targets the KCNMA1 transcript, KCNMA1 protein
expression levels should inversely correlate with that of miR-211
expression levels. A western blot analysis of KCNMA1 expression
was performed, utilizing the same cell lines previously examined
by northern blot (Figure 2B) for KCNMA1 transcript expression.
KCNMA1 protein expression was very low in normal melano-
cytes, but high in all melanoma cell lines (Figure 6A), indicating an
inverse correlation of expression between KCNMA1 protein and
miR-211.
We next investigated whether the induced expression of miR-
211 in melanoma cells can reduce KCNMA1 transcript levels.
qRT-PCR analyses comparing KCNMA1 expression in wild type
WM1552C with that in WM1552C/211(400) revealed that the
introduction of miR-211 down-regulates the KCNMA1 transcript
(Figure 6B). To further address whether KCNMA1 mRNA levels
reflected KCNMA1 protein expression, we performed a western
blot analysis looking for KCNMA1 in cell extracts obtained from:
1) WM1552C, 2) WM1552C/VO (WM1552C cells with a stably-
incorporated empty expression vector), 3) WM1552C/211(400), 4)
WM1552C/211(800), and 5) WM1552C/KC KO (WM1552C
cells with a stably-expressing shRNA against the KCNMA1 mRNA)
(Figure 6C). As expected, KCNMA1 protein levels were
significantly reduced in both melanoma cell lines expressing
miR-211 [even more so in WM1552C/211(800)] compared to
those in WM1552C/VO or untransfected WM1552C cells.
KCNMA1 was virtually undetectable in the WM1552C/KC
KO cell line. These results are consistent with the idea that miR-
211 is able to target the KCNMA1 mRNA, thereby decreasing the
amount of KCNMA1 protein in the cell. miR-211 expression was
measured in engineered melanoma cell lines by qRT-PCR, and it
did not exceed the levels observed in, melanocytes (Figure S2). To
further confirm our observations, we measured the correlation
between miR-211 expression and KCNMA1 protein levels
(Figure 6D). The results revealed an inverted correlation between
miR-211 expression and KCNMA1 protein levels. To confirm
that this expression correlation occurred in non-transformed cells
in addition to cancerous cell lines, we examined the effect of miR-
211 inhibition on the expression of KCNMA1 in melanocytes.
Melanocytes were transfected with anti-miR-211 inhibitors
(Exiqon) and the protein expression of KCNMA1 was measured.
The results indicated that derepression of KCNMA1 protein
expression could be achieved by inhibition of miR-211 (Figure 6E).
miR-211 directly targets the KCNMA1 transcript
To determine whether the computationally predicted target site
of miR-211 in the 39-UTR of the KCNMA1 transcript confers
Figure 2. miR-211 is uniformly under-expressed in all melanoma cell lines. A) Levels of three individual miRNAs, as measured by qRT-PCR in
eight different melanoma cell lines relative to their respective levels in the melanocyte cell line HEM-l, are plotted as histograms. RQ= relative
quantification index. B) Northern blot analysis of miR-211 and miR-let-7g in five melanoma cell lines and melanocytes. miR-let-7g is consistently over-
expressed in melanoma cells. miR-211 is expressed at high level in melanocytes but is not detectable in any of the melanoma cell lines. Error bars are
standard errors of mean of six independent measurements.
doi:10.1371/journal.pone.0013779.g002
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construct containing the 39-UTR of KCNMA1 cDNA fused
downstream of the reporter gene b-galactosidase. The construct,
pcDNA6/LacZ/KCNMA1, as well as a derivative, pcDNA6/
LacZ/KCNMA1-MUT (containing a mutated target cleavage site
at the seed sequence; see Figure S3), and the control vector
pcDNA6/LacZ, were separately transfected into A375 cells along
with one of the following miRNA mimics: miR-211, miR-16-1,
miR-34b, miR-let-7a-1, cel-miR-67, or no mimic (Figure 6E). The
results revealed a statistically significant drop of nearly 60% in b-
galactosidase activity when the cells were transfected with
pcDNA6/LacZ/KCNMA1 together with miR-211 mimics, but
not with any other combination. Importantly, this drop was not
detectable in cells co-transfected with pcDNA6/LacZ/KCNMA1-
MUT and the miR-211 mimic, demonstrating that miR-211 was
capable of specifically targeting the wild type seed sequence in the
39-UTR of the KCNMA1 transcript.
MITF co-ordinately regulates miR-211 and TRPM1
The gene encoding miR-211 is located within the sixth intron of
the TRPM1 gene, which encodes multiple polypeptide isoforms
including melastatin-1, a transient receptor potential (TRP)
protein family member thought to be a potential suppressor of
melanoma metastasis [58]. However, the molecular basis of the
tumor suppressor activity of TRPM1 gene is not understood. The
transcription factor MITF regulates the expression of TRPM1
gene, where the MITF-binding motif (GCTCACATGT) is located
in the TRPM1 promoter [58]. This prompted us to examine
whether MITF also might transcriptionally regulate miR-211
expression via the TRPM1 promoter. We found that both TRPM1
and miR-211 transcripts are expressed in pigmented but not in the
non-pigmented melanoma cells. To determine whether MITF
expression modulates miR-211 expression, we knocked down
MITF expression by siRNA in the pigmented melanoma cell line
SK-MEL28. Three different doses of siRNA (5 nM, 10 nM and
15 nM) were used, and the knock-down efficiency was measured
by qRT-PCR. As expected, the extent of reduction in MITF
transcript levels directly correlated with the reduction in TRPM1
and miR-211 transcript levels (Figure 7). In conclusion, the results
are consistent with the hypothesis that MITF co-ordinately
regulates TRPM1 and miR-211 expression. If true, it raises the
possibility that one of the ways MITF might also suppress
melanoma metastasis is through its transcriptional activation of
miR-211 via the TRPM1 promoter, and the consequent negative
post-transcriptional effects of miR-211 on KCNMA1 mRNA.
The effect of miR-211 on cell proliferation and invasion
Since the over-expression of KCNMA1 is often associated with
both cell proliferation and cell migration/invasion in various
cancers [49–51], we decided to determine whether the depletion of
miR-211 and associated over-expression of KCNMA1 were
important for these processes in melanoma cells. We began by
comparing the proliferation rates of melanoma cell lines stably
transfected with the miR-211 expression cassette with those of
untransfected melanoma cells and cell lines transfected with the
empty expression vector (Figure 8A) (see Methods), respectively.
All miR-211-expressing cultures of WM1552C/211 showed
reduced cell counts compared to those of WM1552C beginning
at even the first time point (day 4), and the titre continued to fall
behind as time progressed. After a 21-day period, WM1552C/
Figure 3. miR-211 expression in clinical melanoma samples. Histograms show normalized ratios of miR-211 levels in clinical samples relative
to its level in the melanocyte cell line HEM-l (normalized to 1.0), as determined by real time quantitative RT-PCR analysis. Normal skin shows low levels
of miR-211 because melanocytes constitute a small fraction of normal skin cells (see text). By two-tailed t-test, the mean RQ of miR-211 in the four
groups (primary melanoma, regional, distant, and nodal metastatic melanoma) compared to the mean RQ of miR-211 in HEM-l were all statistically
significant at P,10
26. MC=Melanocytes, NS=Normal Skin, PM=Primary Melanoma, RM=Regional Metastases, DM=Distant Metastases, and
NM=Nodal Metastases.
doi:10.1371/journal.pone.0013779.g003
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to those of WM1552C, while WM1552C/211(800) cultures
showed an even greater decrease in cell proliferation.
WM1552C/VO cells showed no significant difference in cell
proliferation compared to WM1552C. Comparable results were
obtained for cell proliferation of A375/211 cell lines, which grew
more slowly than untransfected A375 or A375/VO (Figure 8B).
These results are consistent with the hypothesis that an important
growth stimulatory event in the melanoma cell lines WM1552C
and A375 involves the depletion of miR-211 levels—the latter
possibly leading to the targeted up-regulation of at least KCNMA1
expression among its target genes.
Next, we examined the impact of miR-211 expression on the
invasive properties of WM1552C. WM1552C/211(400) and
WM1552C/211(800) cells, along with WM1552C/VO,
WM1552C/KC KO, and untransfected WM1552C cells were
seeded separately into invasion chambers, and the cells were
allowed to migrate (see Methods). Results indicated that
WM1552C/211(400) and WM1552C/211(800) cells migrated
significantly less (,40% and 60% less, respectively) than
WM1552C (Figures 8C and 8D), whereas WM1552C/VO cells
showed almost no variation compared to parental cells. The
frequency of cells with invasion defects significantly exceeded the
decrease in the proliferation rates of these cells (an ,8–10%
decrease in growth over the 48 hours of the invasion assay period),
suggesting that the two effects on miR-211 expression are
independent of each other. The most significant effect on invasion
was observed in the WM1552C/KC KO cells. While a sequence-
scrambled oligonucleotide (miR-Scramble) did not show an effect
on cell invasion, cells treated with a miR-211 inhibitor restored the
invasion phenotype by as much as 40% (Figure 8D). Given that
previously published evidence directly links KCNMA1 gene dosage
and/or expression with increased motility/invasion in several
cancers [49–51], these results suggest that at least part of the
invasion defect caused by miR-211 in melanoma cell lines is due to
targeted down-regulation of the KCNMA1 transcript. To fully
demonstrate that KCNMA1 is a key contributor to miR-211
effects, we examined whether concomitant over-expression of
KCNMA1 might also rescue the miR-211 anti-invasive effects. A
KCNMA1 constitutively-expressing plasmid was transiently trans-
fected into WM1552C/211(800) cells. This plasmid (Origene
clone NM_002247.2) contains a KCNMA1 ORF without its
native 39UTR (making it resistant to regulation by miR-211).
KCNMA1 protein expression levels were then detected by
KCNMA1 antibody. Western blot results revealed that KCNMA1
protein levels were elevated in transfected cells [‘‘WM1552C/
211(800) + KCNMA1 vector’’ relative to control cells] (Figure 8E,
bottom). Results from an invasion assay (Figure 8E, top) illustrate
that the same batch of melanoma cells that exhibit high KCNMA1
protein expression [WM1552C/211(800) + KCNMA1 vector’’
cells] also show high cell invasiveness, higher by at least 60%
compared to the control cell cultures.
Discussion
Current understanding of the molecular mechanisms of
carcinogenesis is beginning to include not only the role of protein
coding genes but also that of non-coding regulatory RNA,
especially miRNAs. In the case of melanoma, our discovery of
miRNAs whose expression levels are reduced in melanoma cells
Figure 4. Expression of predicted target genes of miR-211 in WM1552C. Histograms of log2 transformed mean expression ratios (fold
change) of mRNAs in WM1552C to those in the melanocyte line HEM-l are plotted. The computationally predicted target genes were selected
according to criteria described in Methods. Only genes with statistically significant fold change in expression were plotted.
doi:10.1371/journal.pone.0013779.g004
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responsible for oncogenesis and invasiveness. Along that line, we
report here that miR-211 levels are consistently reduced in
melanoma cells compared to its levels in melanocytes, and that the
expression levels of several potential miR-211 target mRNAs are
elevated in melanoma cells. We demonstrate that the increased
expression of one particular confirmed target transcript,
KCNMA1, is associated with high invasiveness and proliferation
in melanoma cells in vitro.
The simplest model we offer is that the down-regulation of miR-
211 causes elevated levels of KCNMA1 protein in melanoma cells,
which at least in part explains the invasiveness of malignant
melanoma. More complex models are possible, such as yet
unidentified targets of miR-211 (besides KCNMA1) that may have
a positive feedback effect on KCNMA1 levels and are responsible
for invasiveness. Another alternative possibility is that miR-211
down-regulation in melanoma causes other transformational events
unrelated to KCNMA1, leading to higher oncogenesis and
invasiveness. Both of these more complex possibilities are consistent
with some of our results, but not with the full set of results presented
here. While the assays of cell invasion reported here are widely used
for demonstrating metastatic potential [59,60], and the results
appear convincing, further in situ studies with immunodeficient mice
are needed to confirm the role of KCNMA1 in melanoma
invasiveness in vivo. We observed that melanoma cell lines
engineered to express high levels of miR-211 begin to lose
expression shortly after removal from selection, indicating a strong
bias against miR-211 expression during the growth of melanoma
cell lines and suggests that the rapid proliferation of melanoma cells
in culture is directly related to low miR-211 activity in these cells.
Future experiments will explore whether the progressive reduction
inmiR-211 levelsobservedintheseengineered cellsis duetogenetic
or epigenetic changes.
The TRPM1 gene, which contains miR-211sequences in the sixth
intron, was previously suggested to be a suppressor of melanoma
aggressiveness[61,62].We showedhere that thetranscriptionfactor
MITF, which regulates the expression of TRPM1, is also needed for
high-level expression of miR-211. Thus, the regulation by MITF of
both TRPM1 and miR-211 genes can be speculated to have similar
effects on melanoma invasiveness separately through their respec-
tive gene products: the former a Ca
++ channel protein (TRPM1),
and the latter a miRNA targeted against the Ca
++ regulated K
+
channel protein KCNMA1. If true, the invasiveness of melanoma
cells could partly be the result of the breakdown of processes related
to calcium-regulated ion homeostasis. The recent finding that
salinomycin, an inhibitor of K
+ transport, is a selective inhibitor of
Figure 5. Effects of miR-211 over-expression on KCNMA1 gene expression. WM1552C and A375 melanoma cell lines were transfected with
expression cassettes containing the pre-miR-211 sequences, and stable transfectants were selected (see Methods). Expression levels of miR-211 target
genes in HEM-l, A375, WM1552C, A375/211 and WM1552C/211 were measured by hybridization of cDNA (made from total RNA) to Affymetrix
microarrrays. Histograms represent the log2 ratios of expression in different cell lines as indicated in the figure. MC=HEM-l.
doi:10.1371/journal.pone.0013779.g005
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role of KCNMA1 in melanoma cells [63]. We cannot eliminate the
formal possibility that the potential tumor suppressor activity of
TRPM1gene is, at leastinpart,dueto theco-expression ofmiR-211
encoded from within its sixth intron. In Figure 9 we summarize our
results, in light of previous studies, as a simple model of the
mechanism of development of invasive melanoma, which highlights
the role of miR-211.
Figure 6. KCNMA1 mRNA is a direct target of miR-211. A) Western blot analysis of KCNMA1 protein expression in melanocytes and melanoma
cell lines. Lysates were prepared from cultures of cells complementing those analyzed by northern blot in Figure 2B, including HEM-l, WM1552C,
RPMI-7951, SK-MEL2, HT-144, and A375 and probed by Western blotting with antibodies against KCNMA1 or b-tubulin. B) Relative expression of
KCNMA1 mRNA in WM1552C compared to WM1552C expressing miR-211 [WM1552C/211(400)]. Histograms represent relative quantification ratio
(RQ) as measured by qRT-PCR analysis. Assays were performed in triplicate. C) Western blot analysis of KCNMA1 protein expression in WM1552C
stable cell lines. Lysates were prepared from cultures of untransfected WM1552C and WM1552C stably transfected with expression vectors
containing: no miR (WM1552C/VO), miR-211 [both WM1552C/211(400) and WM1552C/211(800)], and an shRNA against the KCNMA1 transcript
(WM1552C/KC KO), respectively, and probed by Western blotting with antibodies against KCNMA1 or b-tubulin. D) Inverse correlation between miR-
211 expression and KCNMA1 protein levels. miR-211 mean RQ was measured by quantitative RT-PCR in three different strains: WM1552C/VO
(normalization standard), WM1552C/211(400), and WM1552C/211(800); KCNMA1 protein levels were measured from relative fluorescence in western
blots normalized against fluorescence intensity in WM1552C/VO and b-tubulin load controls. Error bars are standard errors of mean for mean RQ, and
standard deviations of relative fluorescence intensity. E) Anti-miR-211 inhibitor reverses KCNMA1 protein levels in melanocytes. Melanocytes were
transfected with anti-miR-211 inhibitors, and KCNMA1 protein expression was measured in transfected cells by western blot analysis using a KCNMA1
antibody (b-tubulin was used as a load control). Derepression of KCNMA1 protein in the transfected cells is shown in the lane marked as MC+Inh. MC
and MC+Scr are melanocyte controls. F) Inhibitory effect of miR-211 on mRNA containing the KCNMA1 39-UTR sequences. An expression plasmid
containing the KCNMA1 39-UTR seed sequence for miR-211 was fused to a lacZ reporter gene (labelled, KCNMA1) such that the lacZ mRNA would
contain the KCNMA1 39-UTR sequences (harbouring the miR-211 target site) and was co-transfected into the melanoma cell line A375 with one of the
following synthetic miRNAs: miR-211, miR-16-1, miR-34b, miR-let-7a, miR-CE (cel-miR-67), and no miRNA. Histograms are measurements of b-
galactosidase activity at OD420. To directly confirm the importance of the miR-211 seed sequence, a plasmid containing the LacZ gene was fused to a
mutant KCNMA1 39UTR seed sequence (labelled, KCNMA1 Mutant), and the expression vector itself without any 39-UTR fusion to LacZ (labelled,
positive control) were also included. The assays were performed in triplicate. The only sample with statistically significant difference is indicated by an
asterisk (Kruskal Wallis test, x
2=24.142, P,0.001).
doi:10.1371/journal.pone.0013779.g006
miRNA-211 in Melanoma
PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e13779In contrast to our finding that miR-211 levels in most
melanoma cells and clinical samples were down-regulated, Gaur
et al. [64] previously reported that miR-211 was over-expressed in
6 of 8 tested melanoma lines from the NCI-60 panel of cancer
cells. However, a leave-one-out sensitivity analysis conducted by
Gaur et al. [64] failed to show a significant effect on the confidence
interval when miR-211 expression level was omitted, suggesting
low specificity or sensitivity with respect to miR-211 in those
experiments. Muller et al. [41] compared miRNA expression in
melanoma cell lines with pooled normal human epidermal
melanocytes; miR-211 was not down-regulated in their study. It
is likely that the melanocyte cells (pooled epidermal melanocytes)
these authors used were physiologically and genetically different
from the melanocyte lines we used. Jukic et al., [44] reported that
miR-211 was up-regulated in nevi and dramatically down-
regulated in metastatic melanoma compared to nevi controls.
These results are in agreement with our results and contradict the
results published by Schultz, et al.,[31].
In conclusion, we have demonstrated that miR-211 is down-
regulated in non-pigmented melanoma and its expression is
regulated by the MITF gene. The down-regulation of miR-211
and the corresponding up-regulation of its target transcript
KCNMA1 are therefore important molecular events for melano-
ma development and/or progression.
Methods
Cell lines and clinical samples
The human epidermal melanocyte cell line HEM-l (Scien-
Cell
TM, Catalog # 2200) and primary epidermal melanoyctes –
neonatal (ATCC - PCS-200-012) were grown in MelM media
containing MelGS growth supplements, 0.5% FBS, and pen/strep
solution. The melanoma cell lines examined included: A375 (stage
4, ATCCH Number: CRL-1619), G361 (stage 4, ATCC), LOX-
IMV1 (stage 4, ATCC), HT-144 (stage 4, ATCCH Number: HTB-
63), RPMI-7951 (stage 4, ATCCH Number: HTB-66), SK-MEL2
(stage 4, ATCC), SK-MEL28 (stage 3, ATCC), WM793B (stage 1,
ATCCH Number: CRL-2806), and WM1552C (stage 3, ATCCH
Number: CRL-2808). All melanoma cell lines were grown in
Complete Tu Media containing a 4:1 mixture of MCDB-153
medium with 1.5 g/L sodium bicarbonate and Leibovitz’s L-15
medium with 2 mM L-glutamine, 2% FBS, and 1.68 mM CaCl2.
Information regarding all clinical samples, derived from frozen
samples, is described in Table S1.
miRNA arrays
miRNA NCode
TM version 2 array (Invitrogen) containing 553
human and 427 mouse miRNAs, and the TILDA array (ABI) were
used for miRNA expression profiling. The miRNA samples were
labelled with AlexaFluorH conjugated dendrimers using the direct
labelling kit (Genisphere). We routinely evaluated hybridization
conditions by discriminating between 2 nt variants at internal sites,
and most probes can distinguish between 1 nt variants. The arrays
were scanned with Axon B-4000 (Agilent).
Validation of miRNA array results
Expression levels of all statistically significant and differentially
expressed mRNAs and miRNAs were confirmed by qRT-PCR
using TaqManH expression kits (Applied Biosystems) [65] using
multiple technical and biological replicates. GAPDH was used as
the internal reference probe for normalization of expression values
of mRNA, and RNU48 was used for normalization of miRNA.
RNA analysis by Northern blots used 20 mg of total RNA
concentrated from each sample (melanoma cell lines and
melanocytes), separated on 15% urea denaturing polyacrylamide
gels by electrophoresis. Gels were electroblotted to nylon
membranes, cross-linked by UV, prehybridized in ULTRAhybH-
Oligo (Ambion) for 30 minutes at 42uC, and hybridized with 59-
biotinylated anti-miRNA DNA oligonucleotides (100 nM each) at
42uC overnight, washed, and detected by chemiluminescence
(BrightstarH detection kit, Ambion). Anti-U6 probes were used as a
reference control (at 10 pM).
Microarray data analyses and miRNA target prediction
For the initial transformation of miRNA array data, the
GenePixPro 6.0 global normalization method was employed in
which images and results are normalized together. Statistical
significance tests were Welsh t-test, nonparametric ANOVA, (e.g.,
to select genes that have significantly less within sample variance
compared to between sample variance), and correlation analysis
with Pearson’s product moment r and Spearman’s r. Analysis was
controlled for false discovery rate using q-values, with a priori cut off
point of 10 percent [66,67]. For mRNA expression array data,
commencing with GeneChipH Human Exon 1.0 ST Array
(Affymetrix, Inc.) four probes per exon and roughly 40 probes per
gene, 7 total arrays were analysed (three arrays for melanocyte
RNA, and four arrays for melanoma RNA). Cell files were loaded
into PartekH Genomics Suite
TM (Partek, Inc. St. Louis, Missouri,
USA) under the following algorithm constraints: interrogating
probes selection, RMA background correction, adjusted for GC
content, quintile normalization, log probes using base 2, with probe
set summarization of median polish. Quality control assessment
indicated clear separation based on the cell type. Gene level analysis
use an ANOVA model; yj=m+Tj+J, where m is the mean
expression of the gene, Tj is the tissue type, and J is the error
term. The ANOVA model generated a significance level for each
probe set, along with the fold change, and imputed gene
annotations. miR-211 target set of genes were obtained from public
databases [miRanda, miRbase, miRNAmap, Tarbase, PicTar,
Target ScanS, and DIANA MicroTest (http://www.ncrna.org)],
and the results from ANOVA were matched to obtain the final
target gene list of genes. This target list was imported into Ingenuity
Figure 7. The effect of MITF knock-down on TRPM1 and miR-
211 expression in pigmented melanoma cells; SKMEL-28.
Relative gene expression levels of MITF, TRPM1, and miR-211 in MITF
knock-down cells. Three different doses of MITF siRNA (5 nM, 10 nM
and 15 nM) was used to knock-down MITF gene and expression values
are normalized to scramble siRNA control. Histograms represent the
Ratio of RNA Concentration, as measured by qRT-PCR analysis.
doi:10.1371/journal.pone.0013779.g007
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analysis was run employing direct relationships only, the Ingenuity
knowledgebasegenesasthereferenceset,andwithdown-regulators
as the defined expression value parameter. Allmicroarray data have
been deposited into GEO, and accession number is pending.
Construction of miR-211 expression plasmids
Oligonucleotides complementary to the miR-211 genomic
sequences (miR-211 pre For – ttccctttgtcatccttcgcct and miR-211
pre Rev – aggcgaaggatgacaaagggaa, containing HindIII and BamHI
sites on their respective 59 and 39 ends) were used to amplify the
110 bp pre-miR-211 sequence from human melanocyte genomic
DNA (Amplitaq GoldH, Applied Biosystems) and TOPOH-cloned
into the pCRH4-TOPOH vector (Invitrogen). The construct was
sequenced, and the pre-hsa-miR-211 fragment was sub-cloned into
pcDNA4/myc-HisA (Invitrogen) to create pcDNA4/miR-211. The
KCNMA1 siRNA sequence was derived from SilencerH siRNA
(Ambion, siRNA ID: 112882) and constructed as long complemen-
tary oligos (KCNMA1si For – cgtacttcaatgacaatatttcaagagaatattgt-
cattgaagtacgtctttttt and KCNMA1si Rev – aaaaaagacgtacttcaatga-
caatattctcttgaaatattgtcattgaagtacg, containing HindIII and BamHI
sites on their respective 59 and 39 ends). The oligos were mixed at
100 mM, heated, and amplified through one round of PCR
(Amplitaq GoldH, Applied Biosystems) and then TOPOH-cloned
into the pCRH4-TOPOH vector (Invitrogen). Inserts were se-
quenced and then sub-cloned into pcDNA4/myc-HisA (Invitrogen)
to create pcDNA4/shKCNMA1.
Construction of stable melanoma cell lines
2.5610
5 WM1552C or A375 melanoma cells were seeded into
a single well of a 6-well plate and transfected overnight with 5 mg
pcDNA4/miR-211, pcDNA4/shKCNMA1, or pcDNA4/myc-
HisA (‘‘vector only’’ negative control) using FugeneH 6 (Roche).
The transfected cells were selected at 400 or 800 mg/mL
Zeocin
TM for 15 days, and the presence of the transgene copy
in stable Zeocin
TM-resistant foci was confirmed by PCR
(AmplitaqH Gold, Applied Biosystems). Cell lines were named
WM1552C/211(400) or A375/211(400) when selection was at
400 mg/ml Zeocin
TM, and WM1552C/211(800) when selection
was at 800 mg/ml Zeocin
TM, respectively. The ‘‘vector only’’
control cells were selected at 800 mg/ml Zeocin
TM. WM1552C/
KC KO were selected at 400 mg/ml Zeocin
TM.
Target cleavage assays
The 39 UTR seed sequences of putative target genes were
amplified by PCR (Phusion
TM PCR kit, Finnzymes) from human
Figure 9. A model summarizing the regulation and role of miR-211 in melanoma. MITF, a transcription factor with tumor-suppressor
activity, is active in melanocytes, where it is required for the expression of TRPM1, the structural gene for melatonin-1. miR-211 gene is located within
the sixth intron of TRPM1, which is co-transcribed with the TRPM1 transcript, is processed to active miR-211 and subsequently the latter acts on the
39-UTR of KCNMA1 transcript. We propose that inhibition of KCNMA1 translation is needed for preventing the development of invasive melanoma.
MITF activity is low in melanoma cells, which is expected to reduce TRPM1 as well as miR-211 transcription, therefore would induce the expression of
KCNMA1. While it is widely held on the basis of expression pattern alone that TRPM1 is a putative tumor suppressor, we show that miR-211, contained
within the pre-mRNA of TRPM1 transcript, also has a tumor suppressor activity through its negative regulation on KCNMA1.
doi:10.1371/journal.pone.0013779.g009
Figure 8. Effects of miR-211 over-expression on melanoma cells. A and B: Relative mean cell titers of (A) WM1552C/211(400), WM1552C/
211(800), and WM1552C/VO (vector only) cells to that of WM1552C cells and of (B) A375/211(400) and A375/VO (vector only) cells to that of A375
cells. (C) and (D): Cell invasion assays comparing WM1552C to WM1552C/VO, WM1552C/211(400), WM1552C/211(800), and WM1552C/KC KO stable
derivatives, as well as to WM1552C/211(800) transfected with the Anti-miR miRNA Inhibiter for hsa-miR-211 [labelled ‘‘WM1552C/211(800) + miR-
211’’] or Negative Control #1 (labelled ‘‘WM1552C/211(800) + miR-Scramble’’) over 48 hours. Each assay was performed in triplicate. Statistical
significance is indicated by an asterisk in the figure pertaining to the experimental group delimited by a bar over the histograms (P-value,0.001). E)
The artificial expression of KCNMA1 protein in WM1552C/211(800) cells increases melanoma cell invasiveness. Western blot results show that
KCNMA1 protein levels are elevated in transfected cells [‘‘WM1552C/211(800) + KCNMA1 Vector’’ relative to control cells without KCNMA1 expression
vector] (bottom). b-tubulin was used as a load control. Results from the invasion assay illustrate that the KCNMA1 protein expression increased
melanoma cell invasiveness (top).
doi:10.1371/journal.pone.0013779.g008
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gccttccctatatctaaacaatgcaaaatc, KCNMA1 Rev – aaccggtcacccatc-
caggcgaggagc, the primer set contained 59 NotIo r3 9 AgeIs i t e s ) .T h e
PCR product was cloned into pCRH4-TOPOH (Invitrogen),
confirmed by sequencing, then sub-cloned into the 39 UTR of the
LacZ gene in pcDNA6/V5-His/LacZ (Invitrogen) using the 59 NotI
and 39 AgeI restriction sites and reconfirmed by sequencing
(pcDNA6/LacZ/KCNMA1). The cloned 39UTR of KCNMA1
was mutated using the primers: KC Mut For- TACGCATAT-
GAATTATTAAAACAATTTT and KC Mut Rev - TATGCG-
TAAATTACAATTAATTGTGCT, and used to PCR amplify
pcDNA6/LacZ/KCNMA1 using Quickchange (Stratagene). The
plasmid product was then recovered and confirmed by sequencing
(pcDNA6/LacZ/KCNMA1-MUT, see Figure S4 for mutagenesis).
A375 melanomacelllines were then transfected in triplicate (FugeneH
6, Roche) with 5 mgp l a s m i dD N Ao f :A )p c D N A 6 / L a c Z /
KCNMA1, B) pcDNA6/V5-His/KCNMA1-MUT or C)
pcDNA6/V5-His/LacZ (positive control), and co-transfected (si-
PORT
TM, Ambion) at 100 nM with miRIDIAN microRNA Mimics
(Dharmacon) for A) miR-16-1, B) miR-211, C) miR-34b, D) miR-let-
7a-1, E) miRIDIAN cel-miR-67 (negative control; cel-miR-67 has
been confirmed to have minimal sequence identity with miRNAs in
human, mouse, and rat), or F) no mimic miRNA. After overnight
incubation, cellswerewashed in PBS and reincubated in fresh media.
After 48 hours, cells were harvested by trypsinization, examined for
viability, and samples were prepared for the b-galactosidase assay
using the b-Gal Assay kit (Invitrogen). Samples were incubated
overnight at 37uC, then assayed for b -galactosidase activity in a 96-
well plate format using a FlexStation3 (Molecular Devices).
Western blot analysis of KCNMA1
Total lysates of 5610
5 cells of each cell line were boiled under
denaturing conditions and proteins separated on 6% Tris-Glycine
denaturing polyacrylamide gels by electrophoresis. Proteins
transferred to nitrocellulose membranes were probed with the
following primary antibodies: anti-Slo1 (NeuroMab, UC Davis) at
1/500 and anti-b-tubulin (BD Pharmingen) at 1/2000 according
to standard methods. Blots were probed with horseradish
peroxidase-conjugated secondary antibodies and visualized with
ECL chemiluminescence (Pierce) or Alexa 680-conjugated sec-
ondary antibodies (Molecular Probes) and visualized on the Licor
Odyssesy (Licor).
Growth rate assays for miR-211 stable melanoma cell
lines
Assays were performed using WM1552C, WM1552C/VO,
WM1552C/211(400), WM1552C/211(800), A375, A375/VO,
and A375/211 cell lines. Cells were grown in log phase,
trypsinized, counted using an automated cell counter (Cellome-
terH, Nexcelom Bioscience), and then seeded into 75 cm
2 flasks at
5610
5 cells per flask (in triplicate). Media was changed after
6 hours, and cells were further fed every 48 hours (Complete Tu
Media). At days 4, 10, 15, and 21, cells were trypsinized, counted
(CellometerH, Nexcelom Bioscience), and then reseeded. Each
assay was performed in duplicate for all cell lines.
Invasion assays
BD BioCoat
TM growth factor reduced insert plates (Matrigel
TM
Invasion Chamber 12 well plates) were prepared by rehydrating
the BD Matrigel
TM matrix coating in the inserts with 0.5 mls of
serum-free Complete Tu media for two hours at 37uC. The
rehydration solution was carefully removed from the inserts,
0.5 ml Complete Tu (2% FBS) was added to the lower wells of the
plate, and 2.5610
4 cells suspended in 0.5 ml of serum-free
Complete Tu media were added to each insert well. WM1552C/
211(800) cells were additionally transfected with the Anti-miR
miRNA Inhibiter for hsa-miR-211 as well as Negative Control#1
(Ambion) (miR-Scramble) at a concentration of 100 nM using
siPORT NeoFX (Ambion). Invasion assay plates were incubated
for 48 hours at 37uC. Following incubation, the non-invading cells
were removed by scrubbing the upper surface of the insert. The
cells on the lower surface of the insert were stained with crystal
violet, and each trans-well membrane was mounted on a
microscope slide for visualization and analysis. The slides were
scanned using the Aperio Scanscope XT and visualized using the
Aperio Imagescope v10 software. The number of migrating tumor
cells was counted from each of five images per cell line (including
miR Inhibiter transfected cells) in the central area of the filter. Cell
lines were tested in triplicate, and the assays were performed twice.
Data are expressed as the percent invasion through the membrane
relative to the migration of WM1552C (Wild Type) through the
membrane.
Transfection of Human Melanocytes using Anti-miR-211
Inhibiter molecules
5610
5 HEM-l cells were seeded into wells of a 6-well plate. The
cells were then transfected with FugeneH 6 (Roche) and either
100 nM of anti-miR-211 Inhibitors (Exiqon), 100 nM of anti-miR
Inhibiter Negative Control #1 (‘‘miR-Scramble’’), or transfection
agent only. After 48 hours, the cells were harvested by
trypsinization and counted using an automated cell counter
(CellometerH, Nexcelom Bioscience). 2.5610
5 cells were then
prepared for western blotting (as above).
Transient Expression of KCNMA1 in a stable miR-211-
expressing melanoma cell line
2.5610
5 cells WM1552C/211(800) cells were seeded into wells
of a 6-well plate. 1 well was transfected with 5 mg of KCNMA1-
expressing plasmid (Origene catalog # SC122078) using FugeneH
6 (Roche) and a second well was treated with transfection reagent
only. After 48 hours, the cells were harvested by trypsinization and
counted using an automated cell counter (CellometerH, Nexcelom
Bioscience). 2.5610
4 cells were then utilized for invasion assays (in
triplicate) and 2.5610
5 cells were prepared for western blotting (as
above).
Supporting Information
Figure S1 miR-211 expression in melanocytes, normal skin and
nevus. Both melanocytes and nevus sample indicate a higher
expression of miR-211. Melanocyte A - HEM-l, Melanocyte B -
HEM (neonatal cell line).
Found at: doi:10.1371/journal.pone.0013779.s001 (0.26 MB TIF)
Figure S2 miR-211 expression in stable melanoma cell lines
compared to melanocytes. Two stable miR-211-expressing
WM1552C cell lines, as well as a ‘‘Vector Only’’ (VO) control
cell line, as measured by qRT-PCR relative to levels in the
melanocyte cell line HEM-l, are plotted as histograms. Error bars
are standard errors of mean of three independent measurements.
Found at: doi:10.1371/journal.pone.0013779.s002 (0.24 MB TIF)
Figure S3 Mutagenesis of miR-211 target seed sequence in the
39UTR of KCNMA1. Diagram indicates the four nucleotides
altered in the target seed sequence within the 39UTR of
KCNMA1 relative to the wild type.
Found at: doi:10.1371/journal.pone.0013779.s003 (0.25 MB TIF)
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Found at: doi:10.1371/journal.pone.0013779.s004 (0.72 MB TIF)
Table S2 miR-211 expression levels in clinical samples. Note:
Two-tailed t-test comparisons for miR-211 by mean relative
quantification levels of melanocyte and primary melanoma, as well
as regional, distant, and nodal metastatic melanoma were all
statistically significant at P,0.000001.
Found at: doi:10.1371/journal.pone.0013779.s005 (0.84 MB TIF)
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